Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy

•Most (78%) patients aged ≥ 60 years with ND AML treated with LIT are classified as having 2022 ELN adverse risk.•The Beat-AML 2024 risk model incorporates IDH2, KRAS, MLL2, and TP53 to refine risk stratification among patients aged ≥ 60 years given LIT. [Display omitted] Although the 2022 European...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances 2024-10, Vol.8 (20), p.5297-5305
Hauptverfasser:	Hoff, Fieke W., Blum, William G., Huang, Ying, Welkie, Rina Li, Swords, Ronan T., Traer, Elie, Stein, Eytan M., Lin, Tara L., Archer, Kellie J., Patel, Prapti A., Collins, Robert H., Baer, Maria R., Duong, Vu H., Arellano, Martha L., Stock, Wendy, Odenike, Olatoyosi, Redner, Robert L., Kovacsovics, Tibor, Deininger, Michael W., Zeidner, Joshua F., Olin, Rebecca L., Smith, Catherine C., Foran, James M., Schiller, Gary J., Curran, Emily K., Koenig, Kristin L., Heerema, Nyla A., Chen, Timothy, Martycz, Molly, Stefanos, Mona, Marcus, Sonja G., Rosenberg, Leonard, Druker, Brian J., Levine, Ross L., Burd, Amy, Yocum, Ashley O., Borate, Uma M., Mims, Alice S., Byrd, John C., Madanat, Yazan F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Female Humans Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - therapy Male Middle Aged Mutation Myeloid Neoplasia Prognosis Risk Assessment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!